CD36 as a therapeutic target for endothelial dysfunction in stroke.
about
Potential Roles of Adropin in Central Nervous System: Review of Current LiteratureThrombospondin-1 mediates multi-walled carbon nanotube induced impairment of arteriolar dilationCirculating CD36 and oxLDL levels are associated with cardiovascular risk factors in young subjects.Targeting CD36-mediated inflammation reduces acute brain injury in transient, but not permanent, ischemic stroke.Lymphocytic Microparticles Modulate Angiogenic Properties of Macrophages in Laser-induced Choroidal Neovascularization.CD36 is a co-receptor for hepatitis C virus E1 protein attachment.Long-term intake of animal flesh and risk of developing hypertension in three prospective cohort studies.Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the WoundsBreaking the barrier in stroke: what should we know? A mini-review.Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology.ROS via BTK-p300-STAT1-PPARγ signaling activation mediates cholesterol crystals-induced CD36 expression and foam cell formation.Thrombospondin-1 Gene Deficiency Worsens the Neurological Outcomes of Traumatic Brain Injury in MiceDiabetes insipidus contributes to traumatic brain injury pathology via CD36 neuroinflammation.Sulfosuccinimidyl oleate sodium is neuroprotective and alleviates stroke-induced neuroinflammation.Exposure to traffic-generated air pollutants mediates alterations in brain microvascular integrity in wildtype mice on a high-fat diet.The Contribution of Autoantibodies to Inflammatory Cardiovascular Pathology.
P2860
Q26742073-78A2D493-9C5B-4EA2-94F3-C25D20249F08Q28917103-8368DA36-B91F-41B6-9892-BAF75C2F872CQ33576005-862BD4F0-002D-43BB-BC98-E72FF0270732Q35185434-1AF89379-85E0-4FBF-A7C8-FECA55C3B005Q36200878-96E20128-A4CD-437F-B05A-9952EC46ABCFQ36602246-9766A0CB-CA96-46CA-A169-EE4FEC6F1CD5Q36700562-6F1C2BFF-0900-4421-9319-83750DD6D1F5Q36864027-0B8EE9B2-A640-486A-9C6C-654D33D23CE8Q38009070-60AF0B15-815D-4649-8652-15FE927F7AAEQ38108373-9AED9133-69E8-42C3-B9A5-C5E12D6E012AQ40345587-C5EF2676-AD86-4F9A-BA68-929C01AC8CB6Q41035767-A2055024-9B5C-4C21-BC06-6F0E459F4DBDQ42920728-EE222C7F-9924-4C01-AB18-615DD0D6C2A4Q47110128-1E92233C-106A-4C5C-9BAD-28E8396E94A2Q47407286-11AF29BD-4097-4E9D-8BEA-F1448A54CDC7Q55318081-7342CEC8-21D2-4FA9-8D6E-26E088098CDB
P2860
CD36 as a therapeutic target for endothelial dysfunction in stroke.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
CD36 as a therapeutic target for endothelial dysfunction in stroke.
@ast
CD36 as a therapeutic target for endothelial dysfunction in stroke.
@en
type
label
CD36 as a therapeutic target for endothelial dysfunction in stroke.
@ast
CD36 as a therapeutic target for endothelial dysfunction in stroke.
@en
prefLabel
CD36 as a therapeutic target for endothelial dysfunction in stroke.
@ast
CD36 as a therapeutic target for endothelial dysfunction in stroke.
@en
P2860
P1476
CD36 as a therapeutic target for endothelial dysfunction in stroke.
@en
P2093
Sunghee Cho
P2860
P304
P356
10.2174/138161212802002760
P577
2012-01-01T00:00:00Z